Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• CTO Abhimanyu Verma sold 5,000 SOPHiA GENETICS shares at $7.60 each for $38,000 under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 2.67% to 182,171 shares.
• SOPHiA GENETICS shares traded at $7.67, near their 12-month high of $7.88, but the company reported a quarterly EPS loss of $0.26—worse than the $0.21 consensus estimate—despite revenue exceeding expectations.
• Analyst sentiment remains mixed: three analysts rate the stock Buy, one Hold and one Sell, producing a consensus Hold rating and an average price target of $10.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.60, for a total transaction of $38,000.00. Following the sale, the chief technology officer owned 182,171 shares of the company's stock, valued at $1,384,499.60. This trade represents a 2.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total value of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Trading Down 0.5%

NASDAQ:SOPH traded down $0.04 during trading hours on Monday, hitting $7.67. 408,022 shares of the stock were exchanged, compared to its average volume of 221,806. The company's 50 day moving average is $5.63 and its two-hundred day moving average is $5.15. The company has a market capitalization of $643.44 million, a P/E ratio of -6.67 and a beta of 0.96. SOPHiA GENETICS SA has a twelve month low of $2.96 and a twelve month high of $7.88. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Principal Financial Group Inc. lifted its holdings in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock worth $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Archon Capital Management LLC boosted its stake in SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after purchasing an additional 14,342 shares during the period. Finally, Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS in the 1st quarter valued at $2,157,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SOPH. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright lifted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source